Four monoclonal antibodies (mAbs) are in development for the preventive treatment of migraine. If all goes well, the US Food and Drug Administration will approve more than one of them this year. Three target calcitonin gene–related peptide (CGRP),1 a widely distributed vasodilatory and modulatory neuropeptide that plays an important role in migraine. Another targets the CGRP receptor.1 When these antibodies become available, who should try them? How should physicians, patients, and payers weigh available information about efficacy in the context of uncertainty about long-term safety and likely high costs?
Loder EW, Burch RC. Who Should Try New Antibody Treatments for Migraine? JAMA Neurol. 2018;75(9):1039–1040. doi:10.1001/jamaneurol.2018.1268
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: